Enhancing treatment strategies for small bowel cancer: a clinical review of targeted therapy and immunotherapy approaches

Small bowel cancer (SBC) is a rare and aggressive disease with a poor prognosis, necessitating the exploration of novel treatment approaches. This narrative review examines the current evidence on targeted therapy and immunotherapy for SBC, focusing on the two most common subtypes: adenocarcinoma an...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 2024-07, Vol.397 (7), p.4601-4614
Main Authors: Ebrahimpour, Mehrshad, Hosseinzadeh, Hamidreza, Abedi, Farshad, Nodeh, Mohammad Moeini, Allahyari, Abolghasem, Sahebkar, Amirhossein, Arasteh, Omid
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - immunology
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Bevacizumab
Biomedical and Life Sciences
Biomedicine
Case reports
Clinical trials
Humans
Immunotherapy
Immunotherapy - methods
Intestinal Neoplasms - drug therapy
Intestinal Neoplasms - immunology
Intestinal Neoplasms - therapy
Intestine
Intestine, Small - immunology
Intestine, Small - pathology
Medical prognosis
Molecular Targeted Therapy
Neuroendocrine tumors
Neuroendocrine Tumors - drug therapy
Neuroendocrine Tumors - immunology
Neuroendocrine Tumors - therapy
Neurosciences
Patients
Pembrolizumab
Pharmacology/Toxicology
Review
Small intestine
Survival
Trastuzumab
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small bowel cancer (SBC) is a rare and aggressive disease with a poor prognosis, necessitating the exploration of novel treatment approaches. This narrative review examines the current evidence on targeted therapy and immunotherapy for SBC, focusing on the two most common subtypes: adenocarcinoma and neuroendocrine tumor. A comprehensive search of PubMed, Scopus, and Google Scholar databases was conducted to identify relevant clinical trials and case reports published in English up to September 2023. The review includes 17 clinical trials and 10 case reports, indicating that targeted therapy and immunotherapy can have the potential to improve survival rates in patients with SBC. Notably, promising targeted medicines include bevacizumab, cetuximab, and trastuzumab, while pembrolizumab and nivolumab show potential as immunotherapies. However, it should be noted that the magnitude of the increase in survival rates with these interventions was small. Further research is needed to determine the optimal combination of targeted therapy and immunotherapy for individual patients with SBC.
ISSN:0028-1298
1432-1912
1432-1912
DOI:10.1007/s00210-024-02992-1